The action of Palbociclib on the Cell Cycle of Head and Neck Squamous Cell Carcinoma: A Systematic Review
Abstract This study evaluates the action of Palbociclib in the cell cycle of HPV-negative head and neck squamous cell carcinoma. Initially approved for HER2- and HR + breast cancer. Palbociclib induces cellular senescence, increases the efficacy of Cetuximab, restores p16 function and decreases phosphorylated Rb, suggesting an improvement in survival in both cancers.
Authors
- Ana Cristina da Silva do Amaral Herrera (ORCID: https://orcid.org/0000-0003-2356-7977)
- José de Jesús Aguilera Silva (ORCID: https://orcid.org/0009-0004-2213-4488)
- M.E. Teixeira (ORCID: https://orcid.org/0009-0009-1350-2564)
Institutions
- Pontifícia Universidade Católica do Paraná (BR)
Publication Details
- Journal
- Brazilian Journal of Oncology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1055/s-0045-1811626
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00